Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Disentangling the contributions of dopamine and amyloid burden to age-related changes in cognition and brain network connectivity in healthy older adults

AMYDA

Normal aging is associated with declines in episodic memory and executive functions. Research suggests that around 20-50% of clinically healthy individuals show significant accumulation of amyloid, one of the hallmark biomarkers of Alzheimer’s disease but it has been difficult to establish the functional impact of amyloid burden in healthy older...

Funding Programme
Start Date
End Date
Total Funding
€ 258 766
European Countries Involved

Dissecting Alzheimer’s disease at a single molecule level

SINGLEMOLALZHEIMER

Fibrillar deposits of proteins are the hallmark of amyloid diseases, amongst which Alzheimer’s disease stands out as the most widespread neurodegenerative pathology of the brain. Neuronal dysfunction is currently attributed to the interaction of A-beta oligomers with the plasma membrane. Several scenarios have been proposed, but the mechanisms of...

Funding Programme
Start Date
End Date
Total Funding
€ 164 459
European Countries Involved

Do nanoparticles induce neurodegenerative diseases? Understanding the origin of reactive oxidative species and protein aggregation and mis-folding phenomena in the presence of nanoparticles

NEURONANO

As the use of nanoparticles becomes more prevalent, it is clear that human exposure will inevitably increase. Considering the rapidly ageing European population and the resulting increase in the incidence of neurodegenerative diseases, there is an urgent need to address the risk presented by nanoparticles towards neurodegenerative diseases. It is...

Funding Programme
Start Date
End Date
Total Funding
€ 4 823 050
European Countries Involved

Eco Friendly Tuneable Microwave continuous Flow Reactor for the Synthesis of Lecucettamines in Therapeutic Activity Against Alzheimer's Disease

MICRO-THERAPY

The four-year MICRO-THERAPY is a fully integrated interdisciplinary proposal which will develop a new area of competence in the three partners, Liverpool John Moores University, University of Rennes1 and ManRos Therapeutics. It brings together a powerful set of partners covering fully the three key aspects - microwave engineering, chemistry and...

Funding Programme
Start Date
End Date
Total Funding
€ 653 242
European Countries Involved

Electrically Controlled Protein Conformation on 3D Tissue Scaffolds

ProtEprobe

ProtEprobe takes advantage of the recent cutting edge developments in protein conformation control at the Malliaras group and high sensitive protein sensing using high sensitivity factor triangular silver nanoplates by the fellow. Misfolding of a protein occurs when it becomes trapped in a local potential energy minimum where the conformation...

Funding Programme
Start Date
End Date
Total Funding
€ 269 744
European Countries Involved

Elucidating pathways from hereditary Alzheimer mutations to pathological tau phenotypes

APPTOTAU

Alzheimer’s disease (AD) is a fatal neurodegenerative disease, manifested by a progressive loss of synaptic connectivity, neuronal death and memory impairment. AD affects 1 out of 10 Europeans aged over 65. There are no effective therapies for AD, in part because there is no proven molecular explanation of the steps leading from initial neuronal...

Funding Programme
Start Date
End Date
Total Funding
€ 270 313
European Countries Involved

Enzyme Design of Medical Interest

MEDENZYMEDESIGN

Enzymes are the most efficient, specific and selective catalysts known up to date. Despite the enzyme advantages, not all synthetic processes present a natural enzyme to catalyze and accelerate the reactions. Hence, the design of new stable enzymes for those processes where no biocatalyst is known represents a major challenge for protein...

Funding Programme
Start Date
End Date
Total Funding
€ 223 538
European Countries Involved

Epigenetic regulation of Alzheimer's disease related genes

EpiRegAD

Alzheimer’s disease (AD) and other dementias affect over 7 million individuals in Europe. There is, as yet, no treatment to halt or reverse disease progression despite huge investments into research. The accumulation of the amyloid beta-peptide (Abeta), derived from the amyloid precursor protein (APP) in the brain, is a key factor in the...

Funding Programme
Start Date
End Date
Total Funding
€ 101 275
European Countries Involved

European Patient Organizations in Knowledge Society

EPOKS

The last two decades have witnessed the increasing role of patient, user and civil society organizations (POs and CSOs) in the production of knowledge on diseases and health problems. Rich and detailed studies have shown that this phenomenon entails new forms of activism. It also questions the modes of governance of knowledge, as well as the role...

Funding Programme
Start Date
End Date
Total Funding
€ 1 129 013
European Countries Involved

EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances

EURIPIDES

'We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against...

Funding Programme
Start Date
End Date
Total Funding
€ 9 086 523
European Countries Involved

Evolution of Alzheimer’s Disease: From dynamics of single synapses to memory loss

ABATSYNAPSE

A persistent challenge in unravelling mechanisms that regulate memory function is how to bridge the gap between inter-molecular dynamics of single proteins, activity of individual synapses and emerging properties of neuronal circuits. The prototype condition of disintegrating neuronal circuits is Alzheimer’s Disease (AD). Since the early time of...

Funding Programme
Start Date
End Date
Total Funding
€ 2 000 000
European Countries Involved

eWall for Active Long Living

eWALL

Independent living of senior citizens is one of the main challenges linked to the ageing population, due to the impact on: (a) the life of the elderly people, (b) the national health systems, (c) the insurance companies, (d) the relatives and (e) the care-givers. Senior citizens may suffer from a number of diseases, including the decline in...

Funding Programme
Start Date
End Date
Total Funding
€ 8 838 005
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).